# Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide

> **NCT03411031** · PHASE2 · TERMINATED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 18 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Elotuzumab
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT03411031
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-10-04
- **Primary completion:** 2021-02-18
- **Final completion:** 2021-11-04
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Sponsor no longer providing drug
- **Last updated:** 2023-03-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03411031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03411031, "Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03411031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*